Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 8/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MTOR | P42345 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24828895 | 0.88 | LMNA (0.43) | P2RY6P2RY2P2RY4LMNAMTOR | |
| SCHEMBL24828935 | 0.87 | P2RY6 (0.44) | P2RY6P2RY2P2RY4LMNAMTOR | |
| SCHEMBL24829073 | 0.86 | LMNA (0.42) | P2RY6P2RY2P2RY4LMNAMTOR | |
| SCHEMBL24828941 | 0.85 | P2RY6 (0.40) | P2RY6P2RY2P2RY4LMNAMTOR | |
| SCHEMBL24828954 | 0.85 | LMNA (0.41) | P2RY6P2RY2P2RY4LMNAMTOR | |
| SCHEMBL24828896 | 0.85 | LMNA (0.41) | P2RY6P2RY2P2RY4LMNAMTOR | |
| SCHEMBL24829157 | 0.84 | LMNA (0.41) | P2RY6P2RY2P2RY4LMNAMTOR | |
| SCHEMBL24828971 | 0.84 | LMNA (0.41) | P2RY6P2RY2P2RY4LMNAMTOR | |
| SCHEMBL24828907 | 0.83 | LMNA (0.42) | P2RY6P2RY2P2RY4LMNAMTOR | |
| SCHEMBL24828968 | 0.83 | POLB (0.48) | P2RY6P2RY2P2RY4LMNAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190782-A1 | NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-11541071-B1 | Nucleoside derivatives and methods of use thereof | Ascletis BioScience Co., Ltd (CN) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190782-A1 | NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF | TYMP, NUDT1, PNP | P2RY6 731/4885P2RY2 1449/4885P2RY4 657/4885 |
| US-11541071-B1 | Nucleoside derivatives and methods of use thereof | TYMP, NUDT1, PNP | P2RY6 731/4885P2RY2 1449/4885P2RY4 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.